Skip to main content
. 2020 Mar;8(5):202. doi: 10.21037/atm.2020.01.56

Table 1. Baseline demographic status and comorbidity compared between the non-PM/DM and PM/DM cohorts.

Variable Non-PM/DM cohort (N=13,740) (%) PM/DM cohort (N=1,374) (%) P value
Age, years (SD)* 49.6 (14.4) 49.6 (14.4) 0.8823
Sex >0.99
   Female 9,460 (68.9) 946 (68.9)
   Male 4,280 (31.1) 428 (31.1)
CCI score <0.001
   0 12,163 (88.5) 649 (47.2)
   1 808 (5.9) 470 (34.2)
   2 486 (3.5) 162 (11.8)
   3 or more 283 (2.1) 93 (6.8)
Comorbidity
   Asthma 838 (6.1) 165 (12.0) <0.0001
   Hypertension 3,602 (26.2) 386 (28.1) 0.1321
   Diabetes 1,315 (9.6) 145 (10.6) 0.2398
   COPD 1,067 (7.8) 207 (15.1) <0.0001
   Pneumonia 1,926 (14) 379 (27.6) <0.0001
   Cancer 338 (2.5) 67 (4.9) <0.0001
   CAD 1,708 (12.4) 220 (16.0) 0.0001
   Heart failure 268 (2.0) 66 (4.8) <0.0001
   PVD 41 (0.3) 23 (1.7) <0.0001
Medicine
   Oral steroid 9,544 (69.5) 1,357 (98.8) <0.001
   Methotrexate 897 (65.3)

*, t-test. PM/DM, polymyositis/dermatomyositis; SD, standard deviation; CCI score, Charlson comorbidity index score; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; PVD, pulmonary vascular disease.